Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Gains from Sales and Divestitures (2025)

Beta Bionics' Gains from Sales and Divestitures history spans 1 years, with the latest figure at $275919.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $275919.0; the TTM value through Dec 2025 reached $275919.0, changed N/A, while the annual FY2025 figure was $275919.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $275919.0 at Beta Bionics, up from $190222.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $275919.0 in Q4 2025 and bottomed at $104490.0 in Q2 2025.